Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Timothy L Vollmer

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Neurology
Phone303/724-2187

    Collapse Research 
    Collapse research activities and funding
    U10NS077277     (VOLLMER, TIMOTHY LEE)Sep 30, 2011 - Aug 31, 2018
    NIH/NINDS
    Rocky Mountain Network for Neuroscience Clinical Studies (RMNNCS)
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Beseler C, Vollmer T, Graner M, Yu X. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PLoS One. 2017; 12(10):e0186842. PMID: 29059249.
      View in: PubMed
    2. Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep; 3(3):2055217317725102. PMID: 28839949.
      View in: PubMed
    3. Foley JF, Nair KV, Vollmer T, Stephenson JJ, Niecko T, Agarwal SS, Watson C. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence. 2017; 11:1035-1048. PMID: 28670113.
      View in: PubMed
    4. Tyler KL, Vollmer TL. To PLEX or not to PLEX in natalizumab-associated PML. Neurology. 2017 Mar 21; 88(12):1108-1109. PMID: 28228561.
      View in: PubMed
    5. Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Int J MS Care. 2017 Jan-Feb; 19(1):16-24. PMID: 28243182.
      View in: PubMed
    6. Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017 Jan; 11:18-24. PMID: 28104250.
      View in: PubMed
    7. Bacci ED, Wyrwich KW, Phillips GA, Vollmer T, Guo S. Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2:2055217316673235. PMID: 28607741.
      View in: PubMed
    8. Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016 Sep; 9 Suppl 1:S5-S48. PMID: 27640924.
      View in: PubMed
    9. Ke X, Navaratnam P, Sasane R, Eisenberg Lawrence DF, Friedman HS, Tulsi BB, Vollmer T. Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Curr Med Res Opin. 2016 Sep; 32(9):1589-97. PMID: 27207562.
      View in: PubMed
    10. Calkwood J, Vollmer T, Fox RJ, Zhang R, Novas M, Sheikh SI, Viglietta V. Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. Int J MS Care. 2016 May-Jun; 18(3):138-46. PMID: 27252601; PMCID: PMC4887000.
    11. Vollmer TL, McCarthy M. Autoimmune encephalitis: A more treatable tragedy if diagnosed early. Neurology. 2016 May 03; 86(18):1655-6. PMID: 27037233.
      View in: PubMed
    12. Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett JL, Vollmer TL, Shi FD. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Dec; 59(12):1270-1281. PMID: 26920678.
      View in: PubMed
    13. Phillips G, Guo S, Bender R, Havrdová E, Proskorovsky I, Vollmer T. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord. 2016 Mar; 6:66-72. PMID: 27063626.
      View in: PubMed
    14. Radue EW, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D, You X, Elkins J. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2016 Feb; 23(2):412-5. PMID: 26806217.
      View in: PubMed
    15. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Optimizing treatment success in multiple sclerosis. J Neurol. 2016 Jun; 263(6):1053-65. PMID: 26705122; PMCID: PMC4893374.
    16. Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R. Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurol Sci. 2016 Feb; 37(2):165-79. PMID: 26537494.
      View in: PubMed
    17. McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72. PMID: 26295727.
      View in: PubMed
    18. Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R. The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci. 2015 Oct 15; 357(1-2):8-18. PMID: 26238166.
      View in: PubMed
    19. McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8b. PMID: 25726030.
      View in: PubMed
    20. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56. PMID: 24685276.
      View in: PubMed
    21. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014 Apr; 261(4):773-83. PMID: 24535134.
      View in: PubMed
    22. Zhang CJ, Zhai H, Yan Y, Hao J, Li MS, Jin WN, Su N, Vollmer TL, Shi FD. Glatiramer acetate ameliorates experimental autoimmune neuritis. Immunol Cell Biol. 2014 Feb; 92(2):164-9. PMID: 24275856.
      View in: PubMed
    23. Brück W, Vollmer T. Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus. Nat Rev Neurol. 2013 Dec; 9(12):664-5. PMID: 24275930.
      View in: PubMed
    24. Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 2014 Mar; 3(2):227-36. PMID: 25878010.
      View in: PubMed
    25. Vollmer TL, Robinson MJ, Risser RC, Malcolm SK. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract. 2014 Nov; 14(8):732-44. PMID: 24152240.
      View in: PubMed
    26. Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013 Oct; 70(10):1315-24. PMID: 23921521; PMCID: PMC4106803.
    27. Schwartz CE, Quaranto BR, Rapkin BD, Healy BC, Vollmer T, Sprangers MA. Fluctuations in appraisal over time in the context of stable versus non-stable health. Qual Life Res. 2014 Feb; 23(1):9-19. PMID: 23851975.
      View in: PubMed
    28. Schwartz CE, Quaranto BR, Healy BC, Benedict RH, Vollmer TL. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? Arch Phys Med Rehabil. 2013 Oct; 94(10):1971-81. PMID: 23727344.
      View in: PubMed
    29. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85. PMID: 23725360.
      View in: PubMed
    30. Foley FW, Zemon V, Campagnolo D, Marrie RA, Cutter G, Tyry T, Beier M, Farrell E, Vollmer T, Schairer L. The Multiple Sclerosis Intimacy and Sexuality Questionnaire -- re-validation and development of a 15-item version with a large US sample. Mult Scler. 2013 Aug; 19(9):1197-203. PMID: 23369892.
      View in: PubMed
    31. Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. "Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler. 2013 Jun; 19(7):953-60. PMID: 23257618.
      View in: PubMed
    32. Schwartz CE, Snook E, Quaranto B, Benedict RH, Rapkin BD, Vollmer T. Cognitive reserve and appraisal in multiple sclerosis. Mult Scler Relat Disord. 2013 Jan; 2(1):36-44. PMID: 25877453.
      View in: PubMed
    33. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 Jul; 71(7):604-17. PMID: 22710964.
      View in: PubMed
    34. Schwartz CE, Bode RK, Quaranto BR, Vollmer T. The symptom inventory disability-specific short forms for multiple sclerosis: construct validity, responsiveness, and interpretation. Arch Phys Med Rehabil. 2012 Sep; 93(9):1617-1628.e1. PMID: 22580198.
      View in: PubMed
    35. Schwartz CE, Snook E, Quaranto B, Benedict RH, Vollmer T. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Mult Scler. 2013 Jan; 19(1):87-105. PMID: 22546847.
      View in: PubMed
    36. Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer TL. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. J Neuroimmunol. 2012 May 15; 246(1-2):100-7. PMID: 22465063.
      View in: PubMed
    37. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8. PMID: 22459680; PMCID: PMC3320055.
    38. Schwartz CE, Bode RK, Vollmer T. The symptom inventory disability-specific short forms for multiple sclerosis: reliability and factor structure. Arch Phys Med Rehabil. 2012 Sep; 93(9):1629-1636.e2. PMID: 22446293.
      View in: PubMed
    39. Schowinsky J, Corboy J, Vollmer T, Kleinschmidt-DeMasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012 May; 123(5):751-2. PMID: 22407011.
      View in: PubMed
    40. Schwartz CE, Sprangers MA, Oort FJ, Ahmed S, Bode R, Li Y, Vollmer T. Response shift in patients with multiple sclerosis: an application of three statistical techniques. Qual Life Res. 2011 Dec; 20(10):1561-72. PMID: 22081216.
      View in: PubMed
    41. Shi J, Tu JL, Gale SD, Baxter L, Vollmer TL, Campagnolo DI, Tyry TM, Zhuang Y, Kuniyoshi SM. APOE e4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis. Cogn Behav Neurol. 2011 Sep; 24(3):128-33. PMID: 21945984.
      View in: PubMed
    42. Bomprezzi R, Schafer R, Reese V, Misra A, Vollmer TL, Kala M. Glatiramer acetate-specific antibody titres in patients with relapsing?/?remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011 Sep; 74(3):219-26. PMID: 21615449.
      View in: PubMed
    43. Motl RW, McAuley E, Wynn D, Vollmer T. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. Am J Phys Med Rehabil. 2011 May; 90(5):372-9. PMID: 21389842.
      View in: PubMed
    44. Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol. 2011 Apr; 69(4):721-34. PMID: 21425186; PMCID: PMC3082615.
    45. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011 Jun; 235(1-2):9-17. PMID: 21402415.
      View in: PubMed
    46. Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL. A review of cases of neuromyelitis optica. Neurologist. 2011 Mar; 17(2):98-104. PMID: 21364364.
      View in: PubMed
    47. Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases. Neuroepidemiology. 2011; 36(2):85-90. PMID: 21282965; PMCID: PMC3047764.
    48. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Vollmer T. A pilot study of Latinos with multiple sclerosis: demographic, disease, mental health, and psychosocial characteristics. J Soc Work Disabil Rehabil. 2011; 10(4):211-31. PMID: 22126140.
      View in: PubMed
    49. Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011 Feb; 17(2):181-91. PMID: 21135022.
      View in: PubMed
    50. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011 Nov; 82(11):1296-8. PMID: 20935322.
      View in: PubMed
    51. Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 Aug; 124(2):135-41. PMID: 20880264; PMCID: PMC3394540.
    52. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010 Aug 10; 75(6):568-70. PMID: 20697110.
      View in: PubMed
    53. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi FD. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 2010 Aug 30; 207(9):1907-21. PMID: 20696699; PMCID: PMC2931174.
    54. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 Mar 30; 74(13):1041-7. PMID: 20350978; PMCID: PMC2848107.
    55. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr; 9(4):381-90. PMID: 20163990.
      View in: PubMed
    56. Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010 Feb; 26(2):493-500. PMID: 20014979.
      View in: PubMed
    57. Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology. 2010 Jan 05; 74 Suppl 1:S41-6. PMID: 20038762.
      View in: PubMed
    58. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Huang C, Vollmer T. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010; 20(4):451-7. PMID: 21305836.
      View in: PubMed
    59. Buchanan RJ, Minden SL, Chakravorty BJ, Hatcher W, Tyry T, Vollmer T. A pilot study of young adults with multiple sclerosis: demographic, disease, treatment, and psychosocial characteristics. Disabil Health J. 2010 Oct; 3(4):262-70. PMID: 21122795.
      View in: PubMed
    60. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010 Jan; 221(1):136-45. PMID: 19879259.
      View in: PubMed
    61. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009 Oct 27; 73(17):1394-8. PMID: 19858462; PMCID: PMC2769555.
    62. Vollmer T, Blight AR, Henney HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther. 2009 Oct; 31(10):2215-23. PMID: 19922892.
      View in: PubMed
    63. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct; 66(4):460-71. PMID: 19847908.
      View in: PubMed
    64. Vollmer T, Henney HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin Ther. 2009 Oct; 31(10):2206-14. PMID: 19922891.
      View in: PubMed
    65. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler. 2009 Aug; 15(8):959-64. PMID: 19667022.
      View in: PubMed
    66. Motl RW, Schwartz CE, Vollmer T. Continued validation of the Symptom Inventory in multiple sclerosis. J Neurol Sci. 2009 Oct 15; 285(1-2):134-6. PMID: 19592041.
      View in: PubMed
    67. Tu JL, Zhao CB, Vollmer T, Coons S, Lin HJ, Marsh S, Treiman DM, Shi J. APOE 4 polymorphism results in early cognitive deficits in an EAE model. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):466-70. PMID: 19422789.
      View in: PubMed
    68. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. 2009 Feb 01; 182(3):1730-9. PMID: 19155522.
      View in: PubMed
    69. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler. 2009 Mar; 15(3):385-92. PMID: 19153176.
      View in: PubMed
    70. Buchanan RJ, Chakravorty BJ, Tyry T, Hatcher W, Vollmer T. Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristics. NeuroRehabilitation. 2009; 25(4):271-8. PMID: 20037220.
      View in: PubMed
    71. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008 Nov 14; 6:100. PMID: 19014588; PMCID: PMC2596785.
    72. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Smoking status over two years in patients with multiple sclerosis. Neuroepidemiology. 2009; 32(1):72-9. PMID: 19001800; PMCID: PMC2824575.
    73. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13; 72(2):117-24. PMID: 18971448; PMCID: PMC2677495.
    74. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009 Jan; 15(1):105-13. PMID: 18845651.
      View in: PubMed
    75. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol. 2008 Oct; 255(10):1473-8. PMID: 18854910.
      View in: PubMed
    76. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 Sep; 14(8):1091-8. PMID: 18728060.
      View in: PubMed
    77. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. 2008 Sep; 255(9):1354-60. PMID: 18677639; PMCID: PMC3057081.
    78. Bai Y, Liu R, Huang D, La Cava A, Tang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, Shi FD. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol. 2008 Jul; 38(7):1877-88. PMID: 18581322.
      View in: PubMed
    79. Motl RW, Snook EM, Wynn DR, Vollmer T. Physical activity correlates with neurological impairment and disability in multiple sclerosis. J Nerv Ment Dis. 2008 Jun; 196(6):492-5. PMID: 18552627.
      View in: PubMed
    80. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008 Jun; 14(5):663-70. PMID: 18424479.
      View in: PubMed
    81. Zhao CB, Coons SW, Cui M, Shi FD, Vollmer TL, Ma CY, Kuniyoshi SM, Shi J. A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin. Biochem Biophys Res Commun. 2008 May 23; 370(1):16-21. PMID: 18339308.
      View in: PubMed
    82. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88. PMID: 18272891.
      View in: PubMed
    83. Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai XF, La Cava A, Shi FD. IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol. 2008 Jan; 67(1):37-46. PMID: 18052963.
      View in: PubMed
    84. Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, Shi FD. Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol. 2007 Dec 01; 179(11):7415-23. PMID: 18025185.
      View in: PubMed
    85. Liu R, Bai Y, Vollmer TL, Bai XF, Jee Y, Tang YY, Campagnolo DI, Collins M, Young DA, La Cava A, Shi FD. IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol. 2008 May; 211(1):14-24. PMID: 18353312.
      View in: PubMed
    86. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008 Mar; 14(2):219-30. PMID: 17942521.
      View in: PubMed
    87. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol. 2007 Oct; 64(10):1407-15. PMID: 17698695.
      View in: PubMed
    88. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, Campagnolo DI, Shi FD, Vollmer TL. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol. 2007 Oct; 125(1):34-42. PMID: 17632037.
      View in: PubMed
    89. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007 Jun 05; 68(23):1971-8. PMID: 17548546.
      View in: PubMed
    90. Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology. 2008 Jan 15; 70(3):185-90. PMID: 17460153.
      View in: PubMed
    91. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. 2007 Jul; 13(6):770-5. PMID: 17525097.
      View in: PubMed
    92. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007 May 15; 256 Suppl 1:S5-13. PMID: 17346747.
      View in: PubMed
    93. Schwartz EI, Smilenov LB, Price MA, Osredkar T, Baker RA, Ghosh S, Shi FD, Vollmer TL, Lencinas A, Stearns DM, Gorospe M, Kruman II. Cell cycle activation in postmitotic neurons is essential for DNA repair. Cell Cycle. 2007 Feb 01; 6(3):318-29. PMID: 17297309.
      View in: PubMed
    94. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007 Apr; 13(3):357-68. PMID: 17439905.
      View in: PubMed
    95. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007 Jan; 127(1-2):35-41. PMID: 16949751.
      View in: PubMed
    96. Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. 2006 Sep; 22(9):1671-8. PMID: 16968570.
      View in: PubMed
    97. Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y, Smrtka J, Vollmer T, Singh I, Markovic-Plese S. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. 2006 Sep; 178(1-2):130-9. PMID: 16870268.
      View in: PubMed
    98. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006 May; 59(5):780-7. PMID: 16634036.
      View in: PubMed
    99. Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol. 2006 May 01; 176(9):5247-54. PMID: 16621990.
      View in: PubMed
    100. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006 Apr 25; 66(8):1235-40. PMID: 16636241.
      View in: PubMed
    101. Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, Vollmer TL. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int Immunol. 2006 Apr; 18(4):537-44. PMID: 16481342.
      View in: PubMed
    102. Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol. 2005 Dec 15; 175(12):7898-904. PMID: 16339525.
      View in: PubMed
    103. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005 Oct 11; 65(7):1066-70. PMID: 16217060.
      View in: PubMed
    104. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: fatigue assessment. Mult Scler. 2005 Oct; 11(5):583-4. PMID: 16193897.
      View in: PubMed
    105. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 2005 Sep; 19(11):1407-21. PMID: 16126908.
      View in: PubMed
    106. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Vollmer T. Validation of the NARCOMS Registry: pain assessment. Mult Scler. 2005 Jun; 11(3):338-42. PMID: 15957517.
      View in: PubMed
    107. Ding Z, Preiningerova J, Cannistraci CJ, Vollmer TL, Gore JC, Anderson AW. Quantification of multiple sclerosis lesion load and brain tissue volumetry using multiparameter MRI: methodology and reproducibility. Magn Reson Imaging. 2005 Apr; 23(3):445-52. PMID: 15862645.
      View in: PubMed
    108. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol. 2005 Mar 01; 174(5):2696-701. PMID: 15728477.
      View in: PubMed
    109. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler. 2005 Feb; 11(1):33-40. PMID: 15732264.
      View in: PubMed
    110. Sheremata WA, Minagar A, Alexander JS, Vollmer T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs. 2005; 19(11):909-22. PMID: 16268663.
      View in: PubMed
    111. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct; 10(5):589-95. PMID: 15471378.
      View in: PubMed
    112. Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler. 2004 Oct; 10(5):511-20. PMID: 15471366.
      View in: PubMed
    113. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004 Jun 08; 62(11):2038-43. PMID: 15184611.
      View in: PubMed
    114. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. 2004 Jun; 36(3):120-9. PMID: 15233411.
      View in: PubMed
    115. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 May 15; 363(9421):1607-8. PMID: 15145635.
      View in: PubMed
    116. Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler. 2003 Oct; 9(5):461-6. PMID: 14582770.
      View in: PubMed
    117. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs. 2003 Jun; 35(3):163-70. PMID: 12830664.
      View in: PubMed
    118. Lepen C, Coyle P, Vollmer T, Blumhardt L, Lilliu H, Beresniak A. Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model. Clin Drug Investig. 2003; 23(9):571-81. PMID: 17535070.
      View in: PubMed
    119. Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans. J Rehabil Res Dev. 2002 Mar-Apr; 39(2):163-74. PMID: 12051461.
      View in: PubMed
    120. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology. 2001 Dec; 57(12 Suppl 5):S16-24. PMID: 11902590.
      View in: PubMed
    121. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]. Neurology. 2001 Dec; 57(12 Suppl 5):S46-53. PMID: 11902595.
      View in: PubMed
    122. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2001 Oct; 33(5):231-9. PMID: 11668881.
      View in: PubMed
    123. Kohama I, Lankford KL, Preiningerova J, White FA, Vollmer TL, Kocsis JD. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J Neurosci. 2001 Feb 01; 21(3):944-50. PMID: 11157080; PMCID: PMC2605383.
    124. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999 Mar 23; 52(5):1072-4. PMID: 10102433.
      View in: PubMed
    125. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999 Jan 01; 52(1):63-70. PMID: 9921850.
      View in: PubMed
    126. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998 Mar; 50(3):701-8. PMID: 9521260.
      View in: PubMed
    127. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol. 1997 Dec; 54(12):1475-80. PMID: 9400356.
      View in: PubMed
    128. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, O'Connor P, Cohen JA, Schapiro RT, Whitham R, Mass MK, Lindsey JW, Shellenberger K. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997 Jun; 54(6):731-6. PMID: 9193208.
      View in: PubMed
    129. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol. 1995 Jul; 52(7):680-6. PMID: 7619024.
      View in: PubMed
    130. Vollmer TL, Gaiser C, Dell'Oca RL, Porteus M, Steinman L, Stevens DA. Coccidioidal antigen reactive CD4+ T-lymphocytes in the cerebrospinal fluid in coccidioides immitis meningitis. J Med Vet Mycol. 1995 Jan-Feb; 33(1):43-8. PMID: 7544405.
      View in: PubMed
    131. Goldstein JM, Waxman SG, Vollmer TL, Lang B, Johnston I, Newsom-Davis J. Subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects. J Neurol Neurosurg Psychiatry. 1994 Sep; 57(9):1138-9. PMID: 8089692; PMCID: PMC1073150.
    132. Goldstein JM, Azizi SA, Booss J, Vollmer TL. Human immunodeficiency virus-associated motor axonal polyradiculoneuropathy. Arch Neurol. 1993 Dec; 50(12):1316-9. PMID: 8257309.
      View in: PubMed
    133. Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA. Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges. Arch Neurol. 1993 Sep; 50(9):925-30. PMID: 8363446.
      View in: PubMed
    134. Redmond DE, Robbins RJ, Naftolin F, Marek KL, Vollmer TL, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, et al. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients. Res Publ Assoc Res Nerv Ment Dis. 1993; 71:325-59. PMID: 8417471.
      View in: PubMed
    135. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. 1992 Nov 26; 327(22):1541-8. PMID: 1435880.
      View in: PubMed
    136. Vollmer TL, Brass LM, Waxman SG. Lhermitte's sign in a patient with herpes zoster. J Neurol Sci. 1991 Dec; 106(2):153-7. PMID: 1802963.
      View in: PubMed
    137. Vollmer TL, Waldor MK, Steinman L, Conley FK. Depletion of T-4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: a model of superinfection in AIDS. J Immunol. 1987 Jun 01; 138(11):3737-41. PMID: 3108372.
      View in: PubMed
    Vollmer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)